Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 1/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5326014 | 0.93 | ACACB (0.35) | RAMP1CALCRLHRH3CHRM4ACACB | |
| SCHEMBL4849662 | 0.89 | RAMP1 (0.41) | RAMP1CALCRLADRB2CCR3HRH3 | |
| SCHEMBL5250813 | 0.86 | CCR3 (0.38) | CCR3HRH3CHRM4LRRK2ACACB | |
| SCHEMBL3282588 | 0.85 | ACACB (0.39) | HRH3CHRM4ACACBACACATEAD1 | |
| SCHEMBL5249986 | 0.84 | CCR3 (0.37) | CCR3HRH3LRRK2ACACBACACA | |
| SCHEMBL4718767 | 0.81 | ADRB2 (0.37) | RAMP1CALCRLADRB2LRRK2ENPP2 | |
| SCHEMBL4720727 | 0.81 | ADRB2 (0.37) | RAMP1CALCRLADRB2LRRK2ENPP2 | |
| SCHEMBL4798589 | 0.81 | TEAD1 (0.36) | RAMP1CALCRLADRB2CCR2KCNH2 | |
| SCHEMBL4804839 | 0.80 | TEAD1 (0.39) | RAMP1CALCRLADRB2TEAD1OPRL1 | |
| SCHEMBL3278696 | 0.79 | ACACB (0.36) | CCR3HRH3ACACBACACATEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | RUDOLF KLAUS | 2007-10-25 | — | — | US | claimed |
| WO-2006069754-A9 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-08-09 | — | — | WO | claimed |
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-13 | — | — | US | claimed |
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | RUDOLF KLAUS | 2007-10-25 | — | — | US | disclosed |
| EP-1833484-A1 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069754-A9 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-08-09 | — | — | WO | disclosed |
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-13 | — | — | US | disclosed |
| WO-2006069754-A1 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | CALCA, CALCB, CALCR | RAMP1 314/4885CALCRL 5/4885ADRB2 24/4885 |
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | CALCA, CALCB, BDKRB2 | RAMP1 303/4885CALCRL 5/4885ADRB2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.